Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 2708 for:    Neoplasms, Germ Cell and Embryonal | Neuroendocrine Tumors

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02743741
Recruitment Status : Recruiting
First Posted : April 19, 2016
Last Update Posted : March 26, 2019
Sponsor:
Collaborators:
Ozmosis Research Inc.
Cancer Care Ontario
Canadian Molecular Imaging Probe Consortium
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumors Drug: Lutetium-177 Octreotate Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 195 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors
Study Start Date : July 2016
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2024


Arm Intervention/treatment
Experimental: Lutetium-177 Octreotate
Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
Drug: Lutetium-177 Octreotate
Radiopharmaceutical
Other Names:
  • Lu-DOTATATE
  • [Lu-177]-DOTATATE




Primary Outcome Measures :
  1. The proportion of patients progression-free using RECIST 1.1 criteria [ Time Frame: Up to 12 months ]

Secondary Outcome Measures :
  1. The overall response rate as determined by structural imaging using RECIST criteria. [ Time Frame: Up to 5 years ]
  2. The biochemical response rate (as defined by biochemical responses: serum chromogranin A and 24 hr urinary 5HIAA). [ Time Frame: Up to 5 years ]
  3. The acute and late adverse effects of Lu-DOTATATE (177Lu) using CTCAE Version 4.03 [ Time Frame: Up to 5 years ]
  4. Overall survival [ Time Frame: Up to 5 years ]
  5. The Quality of Life (QoL) in patients treated with Lu-DOTATATE (177Lu) [ Time Frame: Up to 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Please note that only Ontario residents will be eligible for participation in this trial.

Inclusion Criteria:

  1. Biopsy-proven neuroendocrine tumor
  2. ECOG performance status ≤ 2
  3. Ki-67 index ≤ 30%
  4. Evidence of progressive disease demonstrated by imaging within six months prior to study enrollment as defined by RECIST v1.1.

    • Tumor board discussion of cases to confirm suitability for participation in the clinical trial is required. Review should include but not limited to imaging review, pathology (including Ki 67) and treatment options.
    • Patients with objective evidence (imaging, or biochemical) that is insufficient to be classified by RECIST 1.1 criteria can be eligible if after provincial multidisciplinary tumor board discussion a consensus for progression eligibility is reached.
    • The tumor board would consider exemptions if the magnitude of change is adequate by other definitions (e.g. using structural and contrast patterns and biochemical changes).
    • Where clinically indicated, formal consultation on pathology, diagnostic imaging to facilitate criteria assessment (including 68Ga PET performed as part of the diagnostic procedure) is strongly recommended.
  5. Adequate lab parameters within 2 weeks prior to enrollment:

    • Serum creatinine ≤ 150 μmol/L
    • Calculated CrCl or measured GFR ≥ 30 mL/min (measured GFR may be done within 4 weeks prior to enrollment)
    • Haemoglobin ≥ 90 g/L
    • WBC ≥ 2 x 109/L
    • Platelets ≥ 100 x 109/L
  6. Adequate liver function tests within 2 weeks prior to enrollment:

    • total bilirubin ≤ 5 x ULN
    • ALT ≤ 5 x ULN
    • AST ≤ 5 x ULN
    • alkaline phosphatase ≤ 5 x ULN
  7. Signed informed consent
  8. Patients with extensive bone metastases (e.g. >25% of bone marrow involvement are eligible but requires careful monitoring of hematological reserve
  9. Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  10. Age ≥ 18 years.

Exclusion Criteria:

  1. Life expectancy <12 weeks
  2. An option for curative surgical or medical therapy or local liver embolization is feasible
  3. Candidate for curative and/or debulking surgical resections
  4. Systemic, biologic, other radioisotope, embolization therapies within ≤4 weeks prior to the first dose of 177Lu.
  5. Prior radiotherapy to target lesion(s) within ≤12 weeks prior to study enrollment [radiotherapy to non-target lesions permitted].
  6. Prior therapy with any systemic radionuclide therapy.
  7. Radiotherapy to more than 25% of the bone marrow.
  8. Known brain metastases (unless metastases have been treated and are stable for ≥ 6 months).
  9. Uncontrolled diabetes mellitus
  10. Co-morbidities that may interfere with delivery of 177Lu (e.g. urinary incontinence).
  11. Second cancer(s) with clinical or biochemical progression within the last 3 years.
  12. Pregnancy or breast feeding. Female subjects must be surgically sterile or postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrolment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
  13. Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation, 68Ga or 177Lu administration, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02743741


Contacts
Layout table for location contacts
Contact: Rebecca Wong, M.D. 416-946-2126 rebecca.wong@rmp.uhn.ca

Locations
Layout table for location information
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada
Contact: Rosalyn Juergens, M.D.         
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: David Laidley, M.D.         
Sub-Investigator: Suzanne Richter, M.D.         
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada
Contact: Rebecca Wong, M.D.         
Sunnybrook Odette Cancer Center Recruiting
Toronto, Ontario, Canada
Contact: Sten Myrehaug, M.D.         
Sponsors and Collaborators
University Health Network, Toronto
Ozmosis Research Inc.
Cancer Care Ontario
Canadian Molecular Imaging Probe Consortium

Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT02743741     History of Changes
Other Study ID Numbers: OZM-067
First Posted: April 19, 2016    Key Record Dates
Last Update Posted: March 26, 2019
Last Verified: March 2019

Keywords provided by University Health Network, Toronto:
Somatostatin Receptor Positive Neuroendocrine Tumors

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Somatostatin
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs